EW traders are the worse accounts on CT…MFers really be putting ABCs and 1 2 3s on anything and calling it TA…Learn to Trade you 🤡 🤡 🤡

clearly we rolled over on $BTC and are still bearish after rejecting the daily cloud. D & 4H chart w levels for lower...let's see where we find support.

$SOL tagged $88.40 and lose the level and no bounce yet. UNDER $88.40 ---> $45.76.

$DOGE Daily hit lower LG target doubt it holds Under $0.097 ---> $0.06174 No longs unless it can reclaim $0.12301

$XRP finally hit $1.50 but it's going much lower, here are the W, D & 4h charts

$FARTCOIN see you MUCH lower, hot air is sinking.

$PEPE much lower incoming

$ETH D & 4h charts hitting their HTF targets. Let's see if Daily can hold on today's close.

$AAVE see you much lower

Breaking: Claude just bought another small cap Pharma company Claude took our $50,000 and opened a brand new position in Denali Therapeutics $DNLI It's an earnings play happening later today but here's the reasoning on why they bought: "The immediate catalyst is Wednesday evening's Q1 print. Denali launched AVLAYAH, its enzyme replacement therapy for neurological Hunter syndrome (MPS II), in late March 2026. This earnings call will be the first time management presents commercial launch data publicly: patient starts, payer coverage penetration, and the Lonza manufacturing run-rate. The orphan-disease commercial ramp cadence is the question the market is pricing uncertainly. I think that uncertainty is more favorable than the current share price implies, and the reasoning starts with the competitive picture.REGENXBIO's RGX-121 gene therapy received an FDA Complete Response Letter in February 2026. That CRL effectively leaves AVLAYAH with uncontested US neurologic-Hunter space. There is no approved competing product in this indication. The patient population is roughly 500 in the United States, characteristic of an ultra-rare orphan indication. Pricing at $5,200 per vial puts annual costs between $270K and $811K per patient depending on weight. That pricing sits directly in line with Aldurazyme and Naglazyme, the two most comparable orphan-drug pricing precedents. The research edge on this position came from two specific corrections I made to upstream consensus models. First, AVLAYAH's FDA approval was March 25, 2026, not May 3 as it appeared in several downstream analyses. A wrong approval date would have compressed the commercial launch timeline in any model using it, understating how many commercial weeks the drug has actually had. Second, DNL343, Denali's ALS program, failed a clinical trial in January 2025. It was appearing in multiple consensus inputs as a pending H2 2026 readout, meaning its expected value was being counted in 12-month expected return projections that will never fire. Correcting both errors shifts my base case to a $24.75 price target and 32.6% expected 12-month return. The risks are real: $400 million annual cash burn against $900 million in cash gives roughly a two-year runway, manufacturing scale-up at Lonza is a first commercial product for DNLI, and the orphan population of approximately 500 US patients caps the total addressable ceiling in this indication. The sizing at 4.82% reflects those risks. The position sizes a real bet without overcrowding it. Expected: 1M 7% | 3M 29% | 12M 32.6%"